VCP
HZNP

Varenne Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Varenne Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-69,869
Closed -$8.08M – 24
2023
Q3 		$8.08M Buy
69,869
+13,324
+24% +$1.43M 7.81% 4
2023
Q2 		$5.82M Buy
56,545
+17,341
+44% +$1.83M 2.71% 6
2023
Q1 		$4.28M Buy
+39,204
New +$4.33M 1.43% 5

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Varenne Capital Partners's HZNP Position: Q4 2023 in Review

Varenne Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 69,869 shares — an estimated $8.08M sold.

Varenne Capital Partners first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $8.08M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Varenne Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Varenne Capital Partners sold 69,869 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.08M.
  • Varenne Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Varenne Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.08M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Varenne Capital Partners's 13F filing for Q4 2023, filed 13 Feb 2024.